FATE News and Press, Fate Therapeutics Inc. From 02/23/21

[[ACA]], [[ACAD]], [[ADPT]], [[AGI]], [[AMED]], [[ANSS]], [[APA]], [[AWK]], [[BILI]], [[BKNG]], [[CCRN]], [[CDNA]], [[CHDN]], [[CNXN]], [[CW]], [[DDD]], [[DOOR]], [[DRH]], [[ECPG]], [[EPR]], [[ESI]], [[ESTC]], [[FATE]], [[FNF]], [[FTI]], [[GBT]], [[GEF]], [[GH]], [[HCC]], [[ICLR]], [[INGN]], ...

Fate Therapeutics (NASDAQ:FATE) is scheduled to announce Q4 earnings results on Wednesday, February 24th, after market close.The consensus EPS Estimate is -$0.38 (-2.7% Y/Y) and the consensus Revenue Estimate is $5.05M (+80.4% Y/Y).Over the last 1 year, FATE has beaten EPS estimates 25% of th...

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced t...

SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced t...

Healthcare lagged the broader market last year, but that can change this year. A cyclical upturn as the pandemic abates and pent-up demand can boost healthcare. Best positioned are industry groups within healthcare that can achieve secular growth beyond the cyclical rise. Biot...

In the past 12 months, two of the best-performing biotech stocks were cancer immunotherapy firm Fate Therapeutics (NASDAQ: FATE) and German coronavirus vaccine manufacturer BioNTech (NASDAQ: BNTX) . During this period, Fate Therapeutics and BioNTech have ne...

2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...

SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immu...

Fate Therapeutics (FATE) has priced public offering of ~4.42M shares at $85.50/share and pre-funded warrants to purchase 257,310 common shares at $85.499 per pre-funded warrant, for total gross proceeds of ~$400M.Underwriters' over-allotment is an additional 701,754 shares.Proceeds expec...

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disord...